We are live on ! Find out more
NVCT icon

Nuvectis Pharma
NVCT

36 hedge funds and large institutions have $12.8M invested in Nuvectis Pharma in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 16 increasing their positions, 6 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 6

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

9% more funds holding

Funds holding: 33 → 36 (+3)

1.45% more ownership

Funds ownership: 7.41% → 8.86% (+1.5%)

22% less capital invested

Capital invested by funds: $16.5M → $12.8M (-$3.65M)

Holders
36
Holders Change
+3
Holders Change %
+9.09%
% of All Funds
0.52%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
16
Reduced
6
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$378K
2
Millennium Management
Millennium Management
New York
+$303K
3
BlackRock
BlackRock
New York
+$254K
4
GCP
GSA Capital Partners
United Kingdom
+$244K
5
Renaissance Technologies
Renaissance Technologies
New York
+$235K

Top Sellers

Rank Fund Capital Flow
1
MWM
Moran Wealth Management
Florida
-$215K
2
Marshall Wace
Marshall Wace
United Kingdom
-$101K
3
TRCT
Tower Research Capital (TRC)
New York
-$53.5K
4
DWA
Dorsey Wright & Associates
California
-$18K
5
California State Teachers Retirement System (CalSTRS)
California State Teachers Retirement System (CalSTRS)
California
-$3.72K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$3.24M +$254K +28,444 +8%
Vanguard Group
2
Vanguard Group
Pennsylvania
$2.45M +$28.1K +3,149 +1%
BWP
3
Baldwin Wealth Partners
Massachusetts
$1.18M +$229K +25,660 +22%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$1.1M +$17.8K +1,994 +2%
State Street
5
State Street
Massachusetts
$986K +$90.6K +10,157 +9%
Northern Trust
6
Northern Trust
Illinois
$514K +$61.4K +6,887 +13%
Renaissance Technologies
7
Renaissance Technologies
New York
$432K +$235K +26,400 +104%
Morgan Stanley
8
Morgan Stanley
New York
$382K +$378K +42,351 +1,217%
Millennium Management
9
Millennium Management
New York
$284K +$303K +34,011 New
JMFC
10
J.M. Forbes & Co
Massachusetts
$284K – – –
GCP
11
GSA Capital Partners
United Kingdom
$228K +$244K +27,313 New
Susquehanna International Group
12
Susquehanna International Group
Pennsylvania
$214K +$229K +25,670 New
Marshall Wace
13
Marshall Wace
United Kingdom
$207K -$101K -11,272 -31%
Two Sigma Investments
14
Two Sigma Investments
New York
$190K +$203K +22,771 New
Charles Schwab
15
Charles Schwab
California
$166K – – –
EDRH
16
Edmond de Rothschild Holding
Switzerland
$160K +$171K +19,170 New
Bank of New York Mellon
17
Bank of New York Mellon
New York
$160K – – –
N
18
Nuveen
North Carolina
$99.1K +$10.8K +1,214 +11%
Barclays
19
Barclays
United Kingdom
$85.5K +$79.1K +8,865 +638%
UBS Group
20
UBS Group
Switzerland
$67.2K +$38.2K +4,284 +113%
Bank of America
21
Bank of America
North Carolina
$62.6K +$12.2K +1,367 +22%
RhumbLine Advisers
22
RhumbLine Advisers
Massachusetts
$60.7K – – –
SO
23
STRS Ohio
Ohio
$51K +$20.5K +2,300 +59%
New York State Common Retirement Fund
24
New York State Common Retirement Fund
New York
$48.1K – – –
JP Morgan Chase
25
JP Morgan Chase
New York
$40.9K – – –
1
2

NVCT Hedge Fund Activity: Q4 2023 in Review

36 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Nuvectis Pharma (NVCT) for Q4 2023, worth a combined $12.8M — down 22% from $16.5M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new NVCT positions and 2 closed out — a net gain of 3 holders — while 16 added to existing stakes and 6 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $378K. The largest seller was Moran Wealth Management, exiting entirely with an estimated $215K sold.

  • 36 institutional investors held Nuvectis Pharma (NVCT) as of Q4 2023, up from 33 in Q3 2023.
  • Funds reported $12.8M of Nuvectis Pharma stock for Q4 2023, down 22% quarter-over-quarter.
  • 5 funds opened new Nuvectis Pharma positions in Q4 2023 and 2 closed out, a net change of +3 holders.
  • The largest Nuvectis Pharma buyer in Q4 2023 was Morgan Stanley, an estimated $378K added.
  • The largest Nuvectis Pharma seller in Q4 2023 was Moran Wealth Management, an estimated $215K sold.

Based on aggregated 13F filings for Q4 2023.